Elucidating the role of clofazimine for the treatment of tuberculosis
Elucidating the role of clofazimine for the treatment of tuberculosis
复制标题
DOI：
10.5588/ijtld.16.0073
复制
发表时间：
2016-12-01
影响因子：
4
通讯作者：
Metcalfe, J. Z.
中科院分区：
文献类型：
--
作者：
O'Donnell, M. R.;Padayatchi, N.;Metcalfe, J. Z.
氯法齐明（CFZ）是一种利米非那嗪，是麻风性麻风治疗方案的关键组成部分，现已在临床上恢复用于治疗耐多药结核病（MDR-TB）。观察性研究和一项随机对照试验表明，该药治疗耐多药结核病有效，并有可能缩短治疗时间。动物和转化研究的结果喜忧参半。在本文中，我们回顾了关键的临床、动物和转化数据，以更好地了解CFZ在治疗耐多药结核病和缩短抗结核治疗中的潜在作用。
Clofazimine (CFZ), a riminophenazine and a key component of the treatment regimen for lepromatous leprosy, has been rehabilitated clinically for the treatment of multidrug-resistant tuberculosis (MDR-TB). Observational studies and a randomized control trial suggest efficacy in the treatment of MDR-TB and the potential for treatment shortening. Animal and translational research have shown mixed results. In this article, we review key clinical, animal, and translational data to better understand the potential role of CFZ in the treatment of MDR-TB and in shortening anti-tuberculosis treatment.